*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Summary Sentence: Douglas Friedman, Ph.D. - Challenges and Opportunities in Bioindustrial Manufacturing
Full Summary: Douglas Friedman's topic is Synthetic Biology and BioMADE
GTMI Lunch and Learn vertical banner"Challenges and Opportunities in Bioindustrial Manufacturing"
Douglas Friedman, Ph.D.
Executive Director of the (EBRC) Engineering Biology Research Consortium, BioMADE - EBRC, University of California, Berkeley
Meeting Link: https://primetime.bluejeans.com/a2m/live-event/arwvdrqx
ABSTRACT
The U.S. Department of Defense recently established BioMADE, the Bioindustrial Manufacturing Innovation Institute, to establish an end-to-end domestic biomanufacturing ecosystem and to address technical challenges, education and workforce development, and ELSI-related issues. The tools of modern biotechnology and synthetic biology allow scientists and engineers to synthesize a wide array of molecules across at small-scale. This talk will focus on challenges and opportunities in bioindustrial manufacturing and how to transition from lab-scale synthesis to relevant commercial scale manufacturing. Doug will include discussion of data and design, scale up, downstream processing, and domestic supply chain security in the context of advances in industry and academia.
BIO
Douglas Friedman is CEO of BioMADE, the Bioindustrial Manufacturing Innovation Institute, and Executive Director of the Engineering Biology Research Consortium (EBRC). His primary scientific and technical interests lie in the fields of synthetic biology, biomanufacturing, and modern biotechnology. Doug's policy interests include development of sustainable biotechnology, safeguarding the bioeconomy, and accelerating technical advancement by building diverse, robust community partnerships. He regularly serves as a subject matter expert on emerging biotechnologies, biotechnology policy, and national security topics at the interface of the biological and chemical sciences. Doug participates in more than a dozen external scientific and policy committees and boards.
Prior to his role at EBRC, Doug was a study director and senior program officer with the Board on Chemical Sciences and Technology at the National Academies of Sciences, Engineering, and Medicine. His primary portfolio focused on the advancement of science and engineering at the interface of chemistry and biology, often as they related to national security.
Earlier in his career, Doug performed research in physical organic chemistry and chemical biology in academia and industry. He earned a Ph.D. in Chemistry from Northwestern University and a B.S. in Chemical Biology from the University of California, Berkeley.
